Esperion Therapeutics Inc (ESPR)
1.995
-0.04
(-1.72%)
USD |
NASDAQ |
Nov 04, 16:00
2.01
+0.02
(+0.75%)
After-Hours: 20:00
Esperion Therapeutics Enterprise Value: 471.51M for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 471.51M |
| October 31, 2024 | 473.47M |
| October 30, 2024 | 491.13M |
| October 29, 2024 | 481.32M |
| October 28, 2024 | 491.13M |
| October 25, 2024 | 485.24M |
| October 24, 2024 | 477.39M |
| October 23, 2024 | 475.43M |
| October 22, 2024 | 491.13M |
| October 21, 2024 | 477.39M |
| October 18, 2024 | 473.47M |
| October 17, 2024 | 487.21M |
| October 16, 2024 | 489.17M |
| October 15, 2024 | 491.13M |
| October 14, 2024 | 483.28M |
| October 11, 2024 | 459.73M |
| October 10, 2024 | 444.04M |
| October 09, 2024 | 451.88M |
| October 08, 2024 | 479.36M |
| October 07, 2024 | 473.47M |
| October 04, 2024 | 497.02M |
| October 03, 2024 | 457.77M |
| October 02, 2024 | 430.30M |
| October 01, 2024 | 389.09M |
| September 30, 2024 | 396.94M |
| Date | Value |
|---|---|
| September 27, 2024 | 402.83M |
| September 26, 2024 | 394.98M |
| September 25, 2024 | 389.09M |
| September 24, 2024 | 396.94M |
| September 23, 2024 | 393.02M |
| September 20, 2024 | 402.83M |
| September 19, 2024 | 416.56M |
| September 18, 2024 | 414.60M |
| September 17, 2024 | 422.45M |
| September 16, 2024 | 418.53M |
| September 13, 2024 | 447.96M |
| September 12, 2024 | 416.56M |
| September 11, 2024 | 414.60M |
| September 10, 2024 | 412.64M |
| September 09, 2024 | 406.75M |
| September 06, 2024 | 396.94M |
| September 05, 2024 | 410.68M |
| September 04, 2024 | 430.30M |
| September 03, 2024 | 432.26M |
| August 30, 2024 | 432.26M |
| August 29, 2024 | 416.56M |
| August 28, 2024 | 406.75M |
| August 27, 2024 | 408.72M |
| August 26, 2024 | 418.53M |
| August 23, 2024 | 420.49M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
202.67M
Minimum
Apr 25 2023
1.831B
Maximum
Feb 13 2020
568.04M
Average
525.09M
Median
Enterprise Value Benchmarks
| Perspective Therapeutics Inc | 524.04M |
| Nektar Therapeutics | -44.82M |
| Alaunos Therapeutics Inc | 0.8037M |
| Oragenics Inc | 1.901M |
| Cocrystal Pharma Inc | -0.5423M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -61.92M |
| Revenue (Quarterly) | 73.83M |
| Total Expenses (Quarterly) | 71.26M |
| EPS Diluted (Quarterly) | -0.33 |
| Gross Profit Margin (Quarterly) | 78.86% |
| Profit Margin (Quarterly) | -83.87% |
| Earnings Yield | -43.11% |
| Operating Earnings Yield | 1.65% |
| Normalized Earnings Yield | -28.97 |